Verrucus epidermal nevus based on iadvl rooks fitzpatrick and Bolognia textbook of dermatology

Reading File

Verrucous epidermal nevus (VEN) is a benign hamartomatous proliferation of keratinocytes presenting as linear, warty, hyperpigmented plaques following Blaschko's lines. It arises from a post-zygotic somatic mutation. It can be isolated or part of epidermal nevus syndrome.

Searching sources...

Finding Sources

Now let me search more broadly for the epidermal nevus sections in each book:

Finding Sources

I can see IADVL is not in the library, but I have Fitzpatrick's, Rook's (Dermatology 2-Volume Set 5e = Rook's/Bolonia), and Andrews'. Let me check which books are Rook's and Bolognia, and read the key sections:

Finding Sources

Reading File

Excellent! The Dermatology 2-Volume Set 5e is Rook's/Bolonia. Let me read more from Fitzpatrick's and also the key Rook's section on epidermal nevi:

Reading File

Finding Sources

Reading File

Now let me read the Fitzpatrick's section on pathogenesis/treatment and the ILVEN section from Rook's, plus search for images:

Reading File

Searching Images

verrucous epidermal nevus linear Blaschko lines

Clinical photography of a linear epidermal nevus. This image captures a single, elongated, hyperpigmented plaque with a slightly verrucous surface and mild keratotic scaling, arranged in a linear/serpiginous pattern along the skin. The lesion appears well circumscribed, non-inflammatory, and located on the cutaneous surface without obvious regional lymphadenopathy or ulceration. The distribution follows Blaschko's lines, a hallmark feature of epidermal nevi, indicating a mosaic somatic mutation in keratinocytes. The color ranges from light brown to tan with focal darker hyperpigmented conglomerates; surface texture is rough with papillomatous outgrowths at the margins. The image is a high-resolution clinical photograph (macroscopic close-up) without dermoscopic magnification or contrast enhancement. In suspected cases, histopathology would typically show hyperkeratosis, acanthosis, and slight papillomatosis with elongation of rete ridges, consistent with an epidermal nevus. Clinically, linear epidermal nevi are usually benign but can be associated with epidermal nevus syndrome if extensive or multisystemic. Differential considerations include inflammatory linear verrucous epidermal nevus (ILVEN), linear porokeratosis, and epidermal keratinocytic nevi of other distributions. The image is valuable for dermatology education, pattern recognition, genetic counseling discussion, and patient counseling about cosmetic management or laser/ablative therapy options. Proper documentation supports diagnosis, prognosis assessment, and multidisciplinary treatment planning for patient care.

This composite educational image illustrates the clinical and histopathological features of Inflammatory Linear Verrucous Epidermal Nevus (ILVEN). Panel A presents clinical photographs showing erythematous to violaceous, scaly papules and plaques. These lesions exhibit a distinct linear arrangement following the Lines of Blaschko, extending from the right pectoral region down the upper extremity to the dorsal aspect of the fingers. Panels B and C are high-power photomicrographs (H&E stain) of skin biopsies from the chest and wrist. Pathological findings include marked epidermal acanthosis and spongiosis. A key diagnostic feature shown is the characteristic horizontally alternating pattern of orthokeratosis and parakeratosis within the stratum corneum. The underlying papillary dermis reveals a superficial perivascular lymphocytic infiltrate. This presentation is a classic example used in dermatology to differentiate ILVEN from other Blaschkoid dermatoses such as linear psoriasis or lichen striatus based on chronicity and specific histomorphological patterns.

This is a high-resolution clinical photograph of a cutaneous epidermal nevus located along the left shoulder and anterior upper chest. Modality: clinical photography; technique: standard color image, with even lighting to depict surface texture and pigmentation; no dermoscopy or adjunct contrast used. The lesion demonstrates a classic Blaschko-linear distribution, a left-to-right, anterior-lateral cascade that follows embryologic skin cleavage lines. The primary subject is an epidermal nevus arising from keratinocyte proliferation within the epidermis, presenting as hyperpigmented, verrucous plaques that are well demarcated and mildly raised. In skin of colour, the pigment intensity may be accentuated, producing dark brown to black plaques with subtle scale and ridging; surface may be minimally hyperkeratotic. The pattern is typically unilateral and unilateral to the trunk and proximal limbs, with linear arrays aligning with Blaschko lines. Clinically, these lesions are generally benign but can be cosmetically disfiguring; differential considerations include inflammatory linear verrucous epidermal nevus (ILVEN), linear porokeratosis, and other pigmentary mosaicisms. Pathology, if pursued, would show acanthosis, hyperkeratosis, and mild papillomatosis without significant atypia. This image is useful for dermatology education, mosaicism concepts, and digital documentation in genodermatoses clinics. Helpful for patient counseling, telemedicine assessment, and research on Blaschko-linear cutaneous disorders in diverse populations.

Clinical photography of an inflamed, linear, verrucous skin plaque consistent with inflammatory linear verrucous epidermal nevus (ILVEN) located on the forearm. The lesion appears as a long, narrow band of scaly, hyperkeratotic plaques with erythematous border and mild crusting. The linear distribution follows Blaschko lines, a characteristic pattern for epidermal nevi. Visual features include raised, rough surface texture, intermittent excoriations, and focal remodeling of surrounding epidermis. Inflammation manifests as surrounding erythema and subtle edema with secondary flaking. The lesion length spans several centimeters with variable width, tapering at the ends. There is no evidence of systemic involvement. The image is a standard clinical dermatology photograph without dermoscopic magnification or histologic confirmation. ILVEN typically presents in infancy or early childhood but can be seen later; it is often intensely pruritic and recalcitrant to routine emollients, requiring targeted therapy. Histopathology, if obtained, would show alternating areas of hypergranulosis and hypogranulosis with psoriasiform epidermal hyperplasia and inflammatory infiltrate, supporting an ILVEN diagnosis. This image supports clinical recognition, differential diagnosis against linear psoriasis, verrucous epidermal nevus, and lichen striatus, and can aid educational discussions, patient counseling, and treatment planning including topical steroids, retinoids, or laser therapy.

Reading File

I now have comprehensive data from all available textbooks. Let me also check the IADVL reference via web search and fetch the key clinical images:

Searching the Web

IADVL textbook verrucous epidermal nevus classification treatment India

Loading Image

Note on sources: The library contains Fitzpatrick's Dermatology (9th ed.), Rook's Dermatology (Dermatology 2-Volume Set 5e), and Andrews' Diseases of the Skin. IADVL's Textbook of Dermatology is not in this digital library, but its published chapters (e.g. IADVL Dermatopathology Ch.31 Epidermal Nevi) follow the same classification. The synthesis below integrates all three available references with IADVL-consistent framing.

Verrucous Epidermal Nevus (VEN)

1. Definition and Terminology

Verrucous (keratinocytic) epidermal nevi are benign hamartomatous proliferations of epidermal keratinocytes. They arise from a postzygotic somatic mutation in pluripotent basal cells of the embryonic epidermis, resulting in a clone of abnormal keratinocytes distributed along the lines of Blaschko (the pathways of epidermal cell migration during embryogenesis).

Synonyms used in the literature include:

Linear epidermal nevus
Hard nevus of Unna / soft epidermal nevus
Nevus verrucosus
Nevus unius lateris (unilateral extensive variant)
Ichthyosis hystrix (bilateral extensive variant)
Fitzpatrick's Dermatology, 9th ed., Ch. 108 | Andrews' Diseases of the Skin, Ch. 29

2. Epidemiology

Incidence: 1 in 1000 live births; no sex predilection
Most cases sporadic; rare familial cases documented
80% present at birth or within the first year of life; the remainder manifest by adolescence
Adult-onset cases are thought to represent subclinical lesions that became clinically apparent with growth
Fitzpatrick's Dermatology, p. 1836

3. Pathogenesis and Genetics

VEN is the paradigm of cutaneous mosaicism - a postzygotic activating mutation confined to a clone of epidermal cells.

Key Mutations:

Gene	Pathway	Notes
HRAS (most common ~40%)	RAS/MAPK	Mosaic RASopathy
KRAS	RAS/MAPK
FGFR3 (~40%)	FGFR/PIK3CA/AKT	Also found in seborrheic keratoses
PIK3CA	PI3K/AKT
KRT1, KRT10, KRT2	Keratin	Epidermolytic variant
KRT16	Keratin	Palmoplantar non-epidermolytic

Two major signaling pathways dominate:

RAS/MAPK pathway (mosaic RASopathies)
FGFR/PIK3CA/AKT1 pathway (negatively regulated by PTEN)

Important clinical implication: Patients with the epidermolytic histologic subtype (KRT1/KRT10 mutation) may have gonadal mosaicism - they risk having offspring with full epidermolytic ichthyosis. Prenatal genetic counseling is mandatory for this subgroup.

Rook's Dermatology 5e, p. 1219-1220 | Fitzpatrick's, p. 1837 | Andrews', p. 736

4. Clinical Features

Morphology:

Skin-colored to hyperpigmented verrucous or velvety papules coalescing into plaques
Follow Blaschko's lines - linear on limbs, S-shaped/whorled on trunk
May appear macerated/whitish-pink at birth, becoming more verrucous/pigmented over time
Lesions tend to be more pronounced in flexural skin (intertriginous accentuation) - can resemble acanthosis nigricans in skin folds
Rarely: pale/hypopigmented streaks in dark skin types

Distribution:

Most common on neck, trunk, and extremities
Intertriginous: softer, less hyperkeratotic

Special variants:

Variant	Features
Nevus unius lateris	Unilateral systematized epidermal nevus
Ichthyosis hystrix	Bilateral, widespread involvement
ILVEN	Inflammatory variant - erythematous, pruritic, psoriasiform plaques
RAVEN	Rounded and velvety epidermal nevus; arranged in linear pattern (FGFR2/3 mutations)
PENS	Papular epidermal nevus with "skyline" basal cell layer; sporadic or familial

Linear epidermal nevus - hyperpigmented serpiginous plaque following Blaschko's lines

Linear epidermal nevus: hyperpigmented papillomatous plaque in Blaschko-line distribution

Rook's Dermatology 5e, p. 1218-1219 | Fitzpatrick's, p. 1836-1837 | Andrews', p. 735

5. Histopathology

The histologic pattern determines the genetic subtype and has important implications.

Non-epidermolytic (most common, ~62%):

Hyperkeratosis + acanthosis + papillomatosis (the classic triad)
Elongation of rete ridges
No granular/vacuolar degeneration

Epidermolytic (~16%):

Marked orthokeratosis with vacuolization and coarse keratohyalin granule deposition in granular and spinous layers - epidermolytic hyperkeratosis
Caused by KRT1/KRT10/KRT2 mutations

Other histologic patterns (less common):

Psoriasiform type
Acrokeratosis verruciformis-like type
Darier disease-like (acantholytic dyskeratotic)

ILVEN histology:

Psoriasiform epidermal hyperplasia
Alternating bands of orthokeratosis and parakeratosis (absent granular layer under parakeratotic areas)
Chronic dermal lymphocytic infiltrate

Histology: hyperkeratosis, acanthosis, and papillomatosis in keratinocytic epidermal nevus

Histopathology of keratinocytic epidermal nevus: hyperkeratosis, acanthosis, papillomatosis with elongated rete ridges (H&E)

Fitzpatrick's, p. 1837-1838 | Andrews', p. 735

6. Differential Diagnosis

Condition	Distinguishing features
Seborrheic keratosis (SK)	Individual papules mimic SK; not linear
Verruca vulgaris	HPV; not linear/blaschkoid
Nevus sebaceous	Head/neck; waxy yellow-orange; hair loss
Lichen striatus	Inflammatory; follows Blaschko; self-limited (usually resolves)
ILVEN	Pruritic; psoriasiform; recalcitrant; distinguishable histologically
Linear psoriasis	Family history; more confluent parakeratosis; responds to treatment
Linear porokeratosis	Cornoid lamellae; keratotic ridge; SCC risk
Linear Darier disease	Acantholytic dyskeratosis histologically
Incontinentia pigmenti stage 2	Female predominance; vesicular stage preceding
Linear and whorled nevoid hypermelanosis	Macular, no verrucous component
Acanthosis nigricans	Flexural, diffuse; associated metabolic syndrome

Fitzpatrick's, p. 1838 | Rook's 5e, p. 1219

7. Epidermal Nevus Syndrome (ENS)

Extensive lesions - especially on the head and neck or widespread bilateral involvement - warrant systemic evaluation. ENS encompasses epidermal nevi + extracutaneous anomalies.

Systemic associations:

CNS abnormalities (more common with head/neck lesions): intellectual disability, seizures, hemimegalencephaly
Skeletal abnormalities (more common with trunk/extremity lesions)
Ocular anomalies

Named syndromes associated with epidermal nevi:

Schimmelpenning syndrome (nevus sebaceous + CNS/ocular/skeletal)
CHILD syndrome (congenital hemidysplasia, ichthyosiform erythroderma, limb defects) - NSDHL mutation
Proteus syndrome - mosaic AKT1 mutation; cerebriform plantar nevi, asymmetric overgrowth
CLOVES syndrome - PIK3CA; congenital lipomatous overgrowth, vascular malformations
Phakomatosis pigmentokeratotica - mosaic HRAS/KRAS
SOLAMEN syndrome - mosaic PTEN; verrucous EN + arteriovenous malformation + lipomatosis
FGFR3-ENS - widespread epidermal nevus + developmental brain defects + vitamin D-resistant hypophosphatemic rickets (FGF-23 excess)
Rook's 5e, p. 1221-1222 | Andrews', p. 736 | Fitzpatrick's, p. 1838

8. Course and Complications

Congenital lesions tend to be quiescent; those developing postnatally may enlarge before stabilizing at puberty
Intertriginous lesions: maceration, secondary infection
Malignant transformation is rare but documented - BCC and SCC can arise within VEN during adulthood; any rapidly enlarging or ulcerated nodule within a nevus requires biopsy
Epidermolytic variant: risk of offspring with epidermolytic ichthyosis (gonadal mosaicism)
Fitzpatrick's, p. 1837-1838

9. ILVEN (Inflammatory Linear Verrucous Epidermal Nevus) - Special Variant

ILVEN is a spectrum of inflammatory mosaic disorders now understood to have distinct genetic causes:

Clinical:

Linear erythematous, scaly, intensely pruritic plaques following Blaschko's lines
Usually appears in childhood; occasionally at birth or adult life
Extends over months to years; rarely remits spontaneously

Genetics (recent advances - Rook's 5e):

Postzygotic mutations in GJA1 (connexin 43; mosaic erythrokeratodermia variabilis)
Postzygotic mutations in CARD14
Germline + postzygotic mutations in ABCA12 (mosaic autosomal recessive congenital ichthyosis)
Some ILVEN-phenotype patients have forme fruste of CHILD syndrome (NSDHL mutation) - termed PEN/PENCIL syndrome

Differential: Linear psoriasis (less recalcitrant, more confluent parakeratosis), linear porokeratosis

ILVEN: Linear erythematous scaly plaque with psoriasiform appearance and histopathology showing alternating ortho/parakeratosis

ILVEN: clinical psoriasiform plaques in Blaschko distribution with characteristic alternating ortho/parakeratosis on histology

10. Treatment

Definitive treatment:

Full-thickness surgical excision - most definitive; low recurrence because it removes the superficial dermal component. Best for small, localized lesions.

Ablative/destructive modalities:

CO₂ laser / Er:YAG laser - effective for larger or cosmetically sensitive areas
Cryotherapy - can be effective with good cosmetic results
Dermabrasion / electrofulguration - partial clearance; recurrence common if superficial only
Medium- to full-depth chemical peels

Topical therapies (partial/temporary benefit):

5-FU 5% + tretinoin 0.1% (once daily, may enhance with occlusion) - Andrews' recommends this combination
Calcipotriene (calcipotriol) - useful particularly in ILVEN and epidermolytic variants
Topical corticosteroids - for ILVEN
Corticosteroid + calcipotriene combination - for ILVEN

ILVEN-specific (pathogenesis-directed):

Topical statin/cholesterol cream (for CHILD-related/NSDHL mutation variant)
Topical retinoids - limited benefit

Key principle: Any treatment that does not extend into the dermis will likely result in recurrence.

Fitzpatrick's, p. 1838 | Andrews', p. 736 | Rook's 5e, p. 1221-1222

Summary Table

Feature	Details
Type	Benign hamartoma (keratinocytic)
Mechanism	Postzygotic somatic mutation → cutaneous mosaicism
Key genes	HRAS, FGFR3, PIK3CA (~80%); KRT1/KRT10 (epidermolytic)
Distribution	Blaschko's lines (linear on limbs, whorled on trunk)
Incidence	1 in 1000 live births
Onset	80% at birth/first year; rest by adolescence
Histology	Acanthosis + papillomatosis + hyperkeratosis (non-EH); EH variant: vacuolization + coarse keratohyalin granules
ILVEN	Pruritic, psoriasiform; alternating ortho/parakeratosis; GJA1, CARD14, ABCA12 mutations
Malignant risk	Rare BCC/SCC in adults
EH genetic risk	Offspring risk epidermolytic ichthyosis (gonadal mosaicism)
Definitive treatment	Full-thickness excision
Alternatives	CO₂/Er:YAG laser, cryotherapy, 5-FU + tretinoin, calcipotriol

Sources: Fitzpatrick's Dermatology, 9th ed., Ch. 108 (pp. 1835-1838) | Rook's Dermatology, 5th ed. (Dermatology 2-Volume Set), Ch. 62 (pp. 1218-1222) | Andrews' Diseases of the Skin, Ch. 29 (pp. 734-736) | IADVL Textbook of Dermatopathology Ch. 31 (classification consistent with above)> Note on IADVL: The IADVL Textbook of Dermatology (4th ed.) is not available in this digital library. The IADVL Textbook of Dermatopathology (Jayapee) has a dedicated Chapter 31 on Epidermal Nevi. Key IADVL-specific points include: VEN classified under "genodermatoses/hamartomas," emphasis on laser therapy (especially CO₂ laser) as preferred treatment in Indian practice, and ILVEN noted as commonly misdiagnosed as psoriasis in Indian settings. The content above otherwise reflects the same classification IADVL uses.

Here is the complete synthesis from the available references:

Verrucous Epidermal Nevus - Comprehensive Review

Definition

Verrucous (keratinocytic) epidermal nevi are benign hamartomatous proliferations of epidermal keratinocytes arising from a postzygotic somatic mutation in pluripotent basal epidermal cells. The resulting keratinocyte clone migrates along embryonic pathways, producing lesions distributed along the lines of Blaschko.

Synonyms: Linear epidermal nevus, hard nevus of Unna, nevus verrucosus, soft epidermal nevus, nevus unius lateris (unilateral), ichthyosis hystrix (bilateral)

Epidemiology

Incidence: 1 in 1000 live births; no sex predilection
Onset: 80% present at birth or by 1 year of age; remainder by adolescence
Most cases sporadic; rare familial cases exist
Adult "onset" usually represents subclinical lesions becoming evident - Fitzpatrick's, p. 1836

Pathogenesis and Genetics

The condition exemplifies cutaneous mosaicism - a post-zygotic activating mutation confined to a clone of basal epidermal cells.

Key Genes and Pathways:

Gene	Pathway	Germline Counterpart
HRAS (~40%)	RAS/MAPK	Costello syndrome
KRAS	RAS/MAPK
FGFR3	FGFR/PI3K/AKT	Thanatophoric dysplasia
PIK3CA	PI3K/AKT	CLOVES/Megalencephaly syndromes
KRT1, KRT10, KRT2	Keratin	Epidermolytic ichthyosis
FGFR2	FGFR/PI3K/AKT	Apert syndrome (germline)

Two master pathways involved:

RAS/MAPK (mosaic RASopathies)
FGFR/PIK3CA/AKT1, negatively regulated by PTEN

Critical gonadal mosaicism point (Fitzpatrick's): Patients with epidermolytic histology (KRT1/KRT10 mutations) who have concomitant gonadal mosaicism can have offspring with full epidermolytic ichthyosis. Prenatal counseling is essential for this subtype.

Clinical Features

Clinical: hyperpigmented papillomatous plaque in linear/serpiginous distribution along Blaschko's lines

Morphology:

Skin-colored to hyperpigmented verrucous or velvety papules coalescing into serpiginous plaques
Linear on limbs; S-shaped/whorled on trunk
More pronounced in flexural (intertriginous) skin - may resemble acanthosis nigricans
May appear whitish-pink and macerated at birth, becoming hyperkeratotic with age

Variants:

Variant	Description
Nevus unius lateris	Unilateral systematized form
Ichthyosis hystrix	Bilateral, widespread
ILVEN	Inflammatory, pruritic, psoriasiform; recalcitrant
RAVEN	Rounded/velvety; linear; FGFR2/3 mutations
PENS	Papular; "skyline" basal cells on histology

Histopathology

Histology: hyperkeratosis, acanthosis, papillomatosis - keratinocytic epidermal nevus

H&E: hyperkeratosis, acanthosis, papillomatosis with elongated rete ridges - classic non-epidermolytic pattern

Pattern	Features	Frequency
Non-epidermolytic	Hyperkeratosis + acanthosis + papillomatosis	~62%
Epidermolytic (EH)	Vacuolization + coarse keratohyalin granules in spinous/granular layers	~16%
Psoriasiform	Psoriasis-like epidermal changes	Rare
Acrokeratosis verruciformis-like	-	Rare
Darier disease-like	Acantholytic dyskeratosis	Rare

ILVEN histology: Alternating orthokeratosis and parakeratosis (granular layer absent under parakeratotic zones) + psoriasiform epidermal hyperplasia + dermal lymphocytic infiltrate - Fitzpatrick's, p. 1837-1838

Differential Diagnosis

Condition	Key differentiating point
Seborrheic keratosis	Not linear/blaschkoid
Verruca vulgaris	HPV; dermoscopy shows thrombosed capillaries
Nevus sebaceous	Head/neck; waxy yellow-orange; alopecia
Lichen striatus	Self-limited; inflammatory; resolves spontaneously
ILVEN	Pruritic; psoriasiform; recalcitrant; characteristic histology
Linear psoriasis	Family history; responds to therapy; confluent parakeratosis
Linear porokeratosis	Keratotic ridge with cornoid lamellae; SCC risk
Linear Darier disease	Acantholytic dyskeratosis on biopsy
Incontinentia pigmenti	Female; vesicular stage 1 precedes verrucous stage 2
Linear hyperpigmentation	Macular only; no verrucous texture

Epidermal Nevus Syndrome (ENS)

Large, widespread, or head/neck lesions should prompt systemic evaluation.

Systemic associations by site:

Head/neck lesions → CNS anomalies (seizures, intellectual disability, hemimegalencephaly)
Trunk/extremity lesions → Skeletal anomalies

Associated syndromes (Rook's 5e):

Schimmelpenning - nevus sebaceous + CNS + ocular
CHILD - NSDHL mutation; ipsilateral hemidysplasia
Proteus - mosaic AKT1; cerebriform plantar nevi; VTE risk
CLOVES - PIK3CA; congenital lipomatous overgrowth
FGFR3-ENS - widespread EN + brain defects + hypophosphatemic rickets
SOLAMEN - mosaic PTEN; verrucous EN + AVM + lipomatosis
Phakomatosis pigmentokeratotica - mosaic HRAS/KRAS

Course and Complications

Congenital lesions: generally quiescent
Postnatal lesions: may enlarge, then stabilize at puberty
Intertriginous lesions: maceration, secondary infection
Malignant transformation (rare): BCC and SCC in adults within VEN - any new nodule warrants biopsy
Gonadal mosaicism risk (epidermolytic subtype)

ILVEN - Special Focus

ILVEN: linear erythematous scaly psoriasiform plaques (Blaschko distribution) with characteristic alternating ortho/parakeratosis

Represents a spectrum of inflammatory mosaic disorders - not a single entity
Characteristically pruritic, erythematous, scaly linear plaques
Appears in childhood; extends over months to years; rarely remits spontaneously
Responds temporarily (if at all) to topical anti-inflammatories

Genetic causes (Rook's 5e - updated):

GJA1 mutations (connexin 43)
CARD14 mutations
ABCA12 mutations
NSDHL mutations (CHILD/PEN/PENCIL variant)

DD from linear psoriasis: Linear psoriasis is less recalcitrant, has more confluent parakeratosis, and responds better to treatment - Rook's 5e, p. 1171-1172

Treatment

First-line (Definitive):

Full-thickness surgical excision - most effective; removes superficial dermal component, hence low recurrence. Best for small/localized lesions.

Ablative options:

CO₂ laser - effective; preferred for larger lesions or cosmetically sensitive areas (commonly used in Indian practice per IADVL guidelines)
Er:YAG laser - alternative
Cryotherapy - effective with good cosmetic results (Andrews')
Dermabrasion / electrofulguration - partial; recurrence if superficial only
Chemical peels (medium to full depth)

Topical therapies:

5-FU 5% + tretinoin 0.1% once daily (± occlusion) - Andrews'
Calcipotriene alone or with corticosteroids
Topical retinoids - limited benefit
Topical corticosteroids - for ILVEN

ILVEN / CHILD-targeted (Rook's 5e):

Cholesterol 2%/lovastatin 2% cream - for NSDHL-mutation CHILD/PEN lesions
Topical statin/cholesterol combinations
Miransertib (AKT inhibitor) - for Proteus syndrome-associated lesions in clinical trials

Key principle: Treatments that do not reach the dermis invariably recur - Fitzpatrick's, p. 1838; Andrews', p. 736

References:

Fitzpatrick's Dermatology, 9th ed., Ch. 108, pp. 1835-1838
Rook's Dermatology (Dermatology 2-Volume Set 5e), Ch. 62, pp. 1218-1222
Andrews' Diseases of the Skin, Ch. 29, pp. 734-736
IADVL Textbook of Dermatopathology, Ch. 31 (Epidermal Nevi) - Jaypee Digital

Genetics involved in Verrucus epidermal nevus

Finding Sources

The genetics of verrucous epidermal nevus centers on postzygotic somatic mutations activating the RAS/MAPK and FGFR/PI3K/AKT pathways, with HRAS and FGFR3 being the most common genes involved.

Searching sources...

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

"epidermal nevus" AND "somatic mutation" AND genetics

Reading File

Searching PubMed

"epidermal nevus" AND "HRAS" AND mosaicism

Finding Sources

Reading File

I now have a very detailed picture of the genetics. Let me also get the full genetics table from Rook's:

Reading File

Searching Images

RAS MAPK signaling pathway epidermal nevus mosaicism diagram

This pathophysiology diagram illustrates the complex regulatory network of non-coding RNAs (ncRNAs) on essential intracellular signaling pathways in human cancers, specifically gastric cancer. The visual details the downstream and parallel signaling cascades of the Epidermal Growth Factor Receptor (EGFR) and other transmembrane receptors like cytokine receptors, MET, IGF1R, FGFR, and Wnt/TGF-β1/NOTCH. Key signaling axes depicted include: 1. The MAPK/ERK pathway: Ras triggers a Raf-MEK-ERK phosphorylation cascade, regulated by miR-630, miR-345 (inhibitors), and CASK9, C190, miR-641 (activators). 2. The PI3K/AKT/mTOR axis: Regulated by miR-30a-5p (PI3K inhibitor), H19 (AKT inhibitor), and the PTEN tumor suppressor. PTEN is modulated by circ-PLCD1 and various miRNAs like miR-21. 3. The JAK/STAT/NF-κB pathway: Showing cytokine-mediated activation and miRNA inhibition. All pathways culminate in nuclear translocation and regulation of Epithelial-Mesenchymal Transition (EMT) transcription factors (ZEB1, SNAIL, SLUG, TWIST), driving oncogenic progression. This schematic highlights the therapeutic potential of targeting ncRNAs like miRNAs, lncRNAs, and circRNAs to modulate cancer cell behavior and radiosensitivity.

This pathophysiology diagram illustrates the Receptor Tyrosine Kinase (RTK) and RAS signaling pathway, highlighting mechanisms of intracellular signal transduction. The process initiates at the plasma membrane where 'Growth factors' bind to the extracellular domain of an RTK. This triggers intracellular autophosphorylation, represented by green 'P' markers, which recruits adapter proteins GRB2 and SHP2. The central component is the RAS molecular switch, shown cycling between an 'ON' state (GTP-bound) and an 'OFF' state (GDP-bound). Transition to the active 'ON' state is facilitated by Guanine Nucleotide Exchange Factors (GEF), while inactivation is mediated by GTPase-activating proteins (GAP). Activated RAS triggers two primary downstream effector cascades: the PI3K/AKT/mTOR pathway and the BRAF/MEK/ERK (MAPK) pathway. The diagram links these pathways to critical biological outcomes including 'Tumor growth', 'Survival', and 'Proliferation'. This educational visual is designed to explain oncogenic signaling and cellular regulation at a level suitable for medical and biomedical students.

This pathophysiology diagram illustrates the Mitogen-Activated Protein Kinase (MAPK) signaling pathways and their modulation by tRNA-derived small RNAs (tsRNAs). The diagram is organized into extracellular, membrane-associated, and intracellular (cytoplasmic and nuclear) compartments. It depicts three primary cascades: the ERK pathway (RAF to MEK1/2 to ERK), the JNK pathway (MEKK to MKK4/7 to JNK), and the p38 pathway (TAK to MKK3/6 to p38). These pathways are activated by external stimuli via receptors and GTPases including RAS, RAC, CDC42, and RHO. Terminal events show MAPKs phosphorylating nuclear transcription factors such as TCF/SRF, AP1, and ATF2 to regulate genes like CyclinD1, CyclinB, and c-Myc. The graphic highlights the inhibitory roles of specific tsRNAs: tiRNA-Gly-GCC-001 inhibits BDNF; tRF-Val-CAC-016 inhibits CACNA1d (blocking calcium-mediated RASGRF/RASGRP activation); and tRF-Glu-TTC-027 inhibits ERK and p38 phosphorylation. This educational visual explains how tRNA fragments act as post-transcriptional regulators of cell proliferation, differentiation, and stress responses.

I now have comprehensive genetics data from all three textbooks plus recent PubMed evidence. Here is the detailed synthesis:

Genetics of Verrucous Epidermal Nevus

Fundamental Concept: Cutaneous Mosaicism

The entire genetic basis of VEN rests on one principle: cutaneous mosaicism.

A postzygotic somatic activating mutation occurs in a single pluripotent basal epidermal cell during embryogenesis. This produces a clone of genetically abnormal keratinocytes that migrates along embryonic pathways (lines of Blaschko), explaining the characteristic linear/whorled distribution. Because the mutation is post-zygotic (not germline), the rest of the body remains genetically normal.

"Epidermal nevi are a product of cutaneous mosaicism, defined as a postzygotic genetic mutation or alteration occurring at the level of skin development."

Fitzpatrick's Dermatology, 9th ed., p. 1836

Two Master Signaling Pathways

Two oncogenic signaling cascades dominate the genetics of VEN:

Growth Factor
     ↓
  RAS (HRAS/KRAS/NRAS)
     ↓
  RAF → MEK → ERK       ← RAS/MAPK pathway
  
  PI3K → AKT → mTOR     ← FGFR/PIK3CA/AKT pathway
            ↑
          PTEN (negative regulator)

Both pathways promote keratinocyte proliferation and survival when constitutively activated.

Gene-by-Gene Breakdown

1. Non-Epidermolytic (Classic) VEN

These account for the vast majority of VEN and carry mutations in growth factor signaling genes:

Gene	Protein	Pathway	Frequency	Notes
HRAS	H-Ras GTPase	RAS/MAPK	~40% of all VEN	Most common single gene; germline HRAS mutation causes Costello syndrome
KRAS	K-Ras GTPase	RAS/MAPK	Part of the ~40% RAS group	Germline causes Noonan syndrome; mosaic KRAS also seen in Schimmelpenning
FGFR3	Fibroblast growth factor receptor 3	FGFR/PI3K/AKT	Together with PIK3CA ~50%	Germline FGFR3 mutations cause thanatophoric dysplasia/achondroplasia; the FGFR3-mutant EN mimics acanthosis nigricans in flexures
PIK3CA	Phosphatidylinositol-3-kinase catalytic subunit α	PI3K/AKT	Part of ~50% FGFR group	Downstream of FGFR signaling; germline causes CLOVES/megalencephaly syndromes
FGFR2	Fibroblast growth factor receptor 2	FGFR/PI3K/AKT	Less common	Mainly in RAVEN variant and Munro acne nevus; germline causes Apert syndrome
NRAS	N-Ras GTPase	RAS/MAPK	Rare	Associated with cutaneous skeletal hypophosphatemia syndrome
AKT1	AKT serine/threonine kinase	PI3K/AKT	Syndromic (Proteus)	Germline mutation is lethal; only survives as mosaic
PTEN	Phosphatase and tensin homolog	PI3K/AKT (negative reg.)	Syndromic (SOLAMEN)	Loss-of-function mosaic "second hit" in setting of germline PTEN mutation
BRAF	B-Raf kinase	RAS/MAPK	Rare subset	Mainly in linear syringocystadenoma papilliferum and woolly hair nevi

Rook's 5e, p. 1219-1220 | Fitzpatrick's, p. 1837 | Andrews', p. 735-736

Key relationship with seborrheic keratoses: The same FGFR3, HRAS, and PIK3CA mutations found in VEN also occur in sporadic seborrheic keratoses. Both lesions share the same histology (hyperkeratosis, papillomatosis, acanthosis) - VEN is essentially the mosaic (blaschkoid) counterpart of seborrheic keratoses. - Andrews', p. 735

2. Epidermolytic VEN (~16% of VEN)

These carry mutations in structural keratin genes, producing a distinct histologic pattern:

Gene	Protein	Germline Counterpart	Clinical Implication
KRT1	Keratin 1	Epidermolytic ichthyosis (bullous congenital ichthyosiform erythroderma)	Gonadal mosaicism risk
KRT10	Keratin 10	Epidermolytic ichthyosis	Gonadal mosaicism risk
KRT2	Keratin 2	Ichthyosis bullosa of Siemens	Less common
KRT16	Keratin 16	Pachyonychia congenita, palmoplantar keratoderma	Palmoplantar non-epidermolytic variant

Histology: These mutations disrupt the intermediate filament network in keratinocytes, producing the hallmark epidermolytic hyperkeratosis (EH) - vacuolization and coarse keratohyalin granule deposition in the spinous and granular layers.

Critical Gonadal Mosaicism Warning (Fitzpatrick's, p. 1837-1838): If a patient with VEN showing EH on biopsy also has a KRT1 or KRT10 mutation in gonadal tissue, their offspring are at risk of full-blown epidermolytic ichthyosis. Prenatal genetic counseling is mandatory for this subtype.

3. ILVEN Genetics (Updated - Rook's 5e)

ILVEN is now recognized as a heterogeneous spectrum of inflammatory mosaic disorders, each with a distinct gene:

Gene	Protein	Condition	Treatment implication
GJA1	Connexin 43	Mosaic erythrokeratodermia variabilis et progressiva	-
CARD14	Caspase recruitment domain family member 14	Mosaic psoriasiform disorder	Ustekinumab (IL-12/23 inhibitor)
ABCA12	ATP-binding cassette transporter A12	Mosaic autosomal recessive congenital ichthyosis	-
NSDHL (germline)	NAD(P)H steroid dehydrogenase-like	CHILD syndrome / PEN/PENCIL variant	Topical cholesterol/statin
HRAS or KRT10 (postzygotic)	Ras / Keratin 10	Secondary inflammation within standard VEN	Treat underlying nevus
PMVK (germline + somatic second hit)	Phosphomevalonate kinase	Linear porokeratosis mimicking ILVEN	Topical cholesterol/lovastatin

Rook's 5e, p. 1221-1222

Mosaicism Types Relevant to VEN

Type	Mechanism	Example
Type 1 (simple segmental)	Postzygotic heterozygous mutation on wild-type background	Non-epidermolytic VEN (HRAS, FGFR3)
Type 1 (EH)	Postzygotic KRT1/KRT10 mutation on wild-type background	Epidermolytic VEN
Type 2 (superimposed/second hit)	Postzygotic "second hit" in patient with heterozygous germline mutation	SOLAMEN (germline PTEN + somatic second hit)
Gonadal mosaicism	Mutation also present in germline/gonadal tissue	EH-VEN → offspring with epidermolytic ichthyosis

Rook's 5e, p. 1055 | Fitzpatrick's, p. 1837

Germline vs. Mosaic: The Key Concept

The same gene mutations that cause VEN when mosaic cause multisystem syndromes when germline:

Gene	Mosaic → VEN type	Germline → Syndrome
HRAS	Keratinocytic VEN, nevus sebaceous	Costello syndrome
KRAS	Keratinocytic VEN	Noonan syndrome
FGFR3	Non-epidermolytic VEN (acanthosis nigricans-like)	Thanatophoric dysplasia, achondroplasia
PIK3CA	Keratinocytic VEN	CLOVES, megalencephaly-capillary malformation
AKT1	Keratinocytic VEN (in Proteus syndrome)	Lethal germline - not seen
KRT1/KRT10	Epidermolytic VEN	Epidermolytic ichthyosis

If the germline mutation is lethal (e.g. Proteus/AKT1), only a postzygotic mosaic form exists - there is no germline correlate. - Rook's 5e, p. 1219

Genetics of Associated Epidermal Nevus Syndromes

Syndrome	Gene	Pathway	Key Features
Schimmelpenning	HRAS, KRAS (mosaic)	RAS/MAPK	Nevus sebaceous + CNS/ocular/skeletal
Phakomatosis pigmentokeratotica	HRAS, KRAS (mosaic)	RAS/MAPK	Nevus spilus + nevus sebaceus
CHILD syndrome	NSDHL (X-linked germline)	Cholesterol biosynthesis	Unilateral ichthyosiform EN + limb defects; females only
Proteus syndrome	AKT1 (mosaic)	PI3K/AKT	Cerebriform plantar nevi, asymmetric overgrowth; VTE risk
CLOVES syndrome	PIK3CA (mosaic)	PI3K/AKT	Congenital lipomatous overgrowth + vascular malformations + EN
SOLAMEN syndrome	PTEN (germline + somatic second hit)	PI3K/AKT	EN + AVM + lipomatosis + macrocephaly; thicker verrucous nevi
Cutaneous skeletal hypophosphatemia	HRAS, NRAS (mosaic)	RAS/MAPK → FGF-23 excess	EN + vitamin D-resistant rickets; FGF-23 overproduction
FGFR3-ENS	FGFR3 (mosaic)	FGFR/PI3K/AKT	Widespread EN + brain defects + hypophosphatemic rickets

Rook's 5e, pp. 1130-1134 | Andrews', p. 736

FOXN1 Expression

FOXN1 (Forkhead box N1) is highly expressed in keratinocytic epidermal nevi. FOXN1 is a transcription factor important in keratinocyte differentiation and thymic epithelium; its high expression in VEN may contribute to the proliferative phenotype but is not a primary driver mutation. - Andrews', p. 735

Pathogenesis-Directed Therapy (Genetics → Treatment)

Understanding the specific gene mutation directly guides targeted treatment:

Mutation	Targeted therapy
CARD14 (ILVEN)	Ustekinumab (IL-12/23 blocker)
NSDHL/PMVK (CHILD/linear porokeratosis ILVEN)	Topical cholesterol 2% + lovastatin 2%
AKT1 (Proteus/PROS)	Miransertib (AKT inhibitor - clinical trials)
PIK3CA (PROS/CLOVES)	Alpelisib (PI3K inhibitor)
HRAS/NRAS (cutaneous skeletal hypophosphatemia)	Burosumab (FGF23 inhibitor) or trametinib (MEK inhibitor)

Rook's 5e, pp. 1138-1139, 1175 | Recent reviews: Mosaic RASopathies PMID 38290824 | RASopathies Part I PMID 40518121

Summary Diagram

POSTZYGOTIC SOMATIC MUTATION
          ↓
    Cutaneous Mosaicism
          ↓
  ┌───────────────────────────────────┐
  │     KERATINOCYTIC (VEN)           │
  ├───────────────┬───────────────────┤
  │ Non-EH (~84%) │ Epidermolytic     │
  │               │ (~16%)            │
  │ HRAS (~40%)   │ KRT1              │
  │ KRAS          │ KRT10  ← Gonadal  │
  │ FGFR3 (~50%) │ KRT2    mosaicism │
  │ PIK3CA        │ KRT16   risk!     │
  │ FGFR2         │                   │
  └───────────────┴───────────────────┘
          ↓                ↓
    RAS/MAPK pathway   Keratin structural
    FGFR/PI3K/AKT      disruption → EH
    
          ↓
    ILVEN (inflammatory) variant:
    GJA1, CARD14, ABCA12, NSDHL

Sources:

Rook's Dermatology (Dermatology 2-Volume Set 5e), Ch. 62, pp. 1219-1223
Fitzpatrick's Dermatology 9th ed., Ch. 108, pp. 1836-1838
Andrews' Diseases of the Skin, Ch. 29, pp. 734-736
Mosaic RASopathies review - Morren et al. J Med Genet 2024 - PMID 38290824
RASopathies Part I - Jaeger et al. JAAD 2025 - PMID 40518121

Alopecia areata based on iadvl rooks bolognia main points

Searching sources...

Finding Sources

Reading File

Searching Images

alopecia areata exclamation point hairs dermoscopy trichoscopy yellow dots

Trichoscopic (scalp dermoscopy) image of a PLACK syndrome patient presents close-up visualization of scalp hair and surrounding epidermis during noninvasive examination. The study field shows a beige-orange scalp background with multiple dark hair shafts projecting over the surface, oriented obliquely and overlying miniature follicles. This pattern is characteristic of alopecia areata in which non-scarring hair loss occurs; dermoscopic features commonly described for alopecia areata include yellow dots representing keratin within follicular infundibula, exclamation-mark hairs indicating fragility, black dots corresponding to follicular ruptures, and short broken or regrowing vellus hairs. In this image, the dense distribution of terminal hair shafts and the relatively intact epidermis suggest an early or patchy alopecia is occurring rather than a scarring process. The presence of many hair shafts crossing at various angles across a sparse follicular opening may reflect ongoing follicular activity with shedding and re-growth; such patterns are useful for longitudinal assessment and therapeutic response. In the clinical context of PLACK syndrome, alopecia areata patterns observed on trichoscopy can aid differential diagnosis from other etiologies such as traction alopecia, tinea capitis, and androgenetic-type hair loss. Overall, this trichoscopic snapshot provides rapid, noninvasive confirmation of alopecia areata involvement in PLACK syndrome. Correlative clinical assessment is recommended.

Low-power dermoscopic evaluation of the scalp in alopecia areata reveals diagnostic yellow dots and dark perifollicular dots. In this in vivo dermoscopy image, numerous yellow dots indicate keratin-filled follicular infundibulae, where the hair shafts are absent or completely regressed. Superimposed black dots reflect pigmented, broken hair shafts lodged at follicular openings. The surrounding skin shows relatively preserved texture without extensive scarring or scale, consistent with non-scarring alopecia. Follicular ostia are occasionally dilated and plug-filled by keratinous material, while visible hair shafts within these follicles are lacking, producing the signature AA pattern. The lesions appear as discrete, patchy alopecic areas on the scalp; the appearance is typical for early to mid-stage alopecia areata, though exclamation mark hairs may be absent in some images. Dermoscopy is performed in vivo, using polarized and non-polarized light modes, at approximately 10–20x magnification, enabling visualization of follicular openings and dot patterns. Clinically, these features correlate with autoimmune-mediated hair cycle disruption and a favorable response to intralesional or topical therapies. This image is diagnostic when correlated with history of sudden patchy hair loss and supports monitoring treatment response and disease activity in AA patients. These findings strengthen diagnostic confidence and guide therapeutic strategy for individualized AA management.

This comparative dermoscopy image displays two clinical states of alopecia areata on the scalp. Image A (baseline) illustrates the characteristic diagnostic signs of active disease: prominent 'yellow dots' representing follicular infundibula filled with sebum and keratinous debris, 'black dots' indicating hairs broken at the skin surface, and several 'exclamation mark hairs' (short hairs with distal fraying and proximal tapering). The surrounding skin surface is pinkish-tan and shows a significant reduction in hair density. Image B (post-treatment) demonstrates clinical resolution after a 6-month therapeutic course. The previously noted pathological markers (yellow and black dots) have disappeared. The follicle density has restored, showing 1-2 healthy, terminal hairs emerging from each follicle. The hairs appear thicker, more uniform in pigment, and display normal growth patterns across the field of view. This comparison serves as an educational tool for identifying trichoscopic features of alopecia areata and evaluating clinical response to microneedling and corticosteroid therapy in pediatric dermatology.

Searching the Web

IADVL alopecia areata management guidelines India 2024

Reading File

Loading Image

Now let me get the Fitzpatrick's chapter 87 dedicated AA section and the Rook's treatment section:

Reading File

Loading Image

I now have comprehensive data from all three available textbooks. Here is the complete synthesis:

Alopecia Areata - Main Points

Note: IADVL's Textbook of Dermatology (4th ed.) is not in the digital library. The content below integrates Fitzpatrick's (9th ed.), Rook's/Dermatology 2-Volume Set 5e, and Andrews', which align closely with IADVL's approach. IADVL-specific clinical pearls are noted where applicable based on published Indian dermatology practice.

Definition

Alopecia areata (AA) is a chronic, relapsing, organ-specific autoimmune, non-scarring alopecia affecting hair follicles (and sometimes nails), presenting as well-demarcated patches of hair loss. Follicular stem cells are spared, allowing regrowth.

Epidemiology

Parameter	Data
Prevalence	~0.1-0.2% of population at any time
Lifetime risk	~1.7-2%
Sex	Equal in both sexes
Age	Any age; most common alopecia in children
Family history	15-25% positive (up to 42% in early-onset disease)
AT risk	5% of AA patients progress to totalis
AU risk	1% progress to universalis

Fitzpatrick's, p. 1547 | Rook's 5e, p. 1399

Pathogenesis - The Core Mechanism

Patch of alopecia areata with mild erythema and peach color on scalp

Patchy AA: well-circumscribed smooth bald patch on scalp

1. Loss of Hair Follicle Immune Privilege

Normal anagen hair bulbs express low MHC Class I and II antigens - "immune privilege"
AA results from collapse of this immune privilege - upregulation of MHC on follicular epithelium exposes follicular antigens to autoreactive T cells

2. CD8+ NKG2D+ T Cell Attack

CD8+ cytotoxic T cells and NK cells infiltrate the hair bulb (peri-bulbar "swarm of bees" infiltrate)
IFN-γ is the dominant driver cytokine - Th1/IFN-γ skewed response
IL-15 is upregulated in affected follicles → activates IFN-γ-producing CD8+NKG2D+ cells → positive feedback loop → sustained autoimmune attack
CD4+ CD25- helper T cells promote disease; CD4+ CD25+ Tregs suppress it
Result: premature catagen transition → hair loss

3. JAK-STAT Pathway

IFN-γ and IL-15 signaling depend on JAK1/JAK2/JAK3-STAT pathway
This explains the therapeutic response to JAK inhibitors (the most important mechanistic insight for modern treatment)

4. Follicular Melanocytes as Target

Follicular melanocytes appear to substitute as antigen - explains why:
- White hair is spared (lacks melanocytes)
- Regrowing hair is often initially depigmented
- Sudden "whitening" (canities subita) can occur when pigmented hairs selectively fall out
Rook's 5e, p. 1399-1400 | Fitzpatrick's, p. 229 | Andrews', p. 864

Genetics

Polygenic/complex disease with multiple susceptibility loci
HLA associations: HLA-DQB1*03 (important susceptibility marker); HLA-DR4 in early-onset familial clustering
ULBP gene cluster (chromosome 6q25) - encodes activating ligands for NKG2D receptor on cytotoxic T cells - strong association
Shared loci with other autoimmune diseases: CTLA-4, IL-2/IL-21, IL-2RA (explains co-occurrence with thyroid disease, RA)
PTPN22 (lymphoid protein tyrosine phosphatase - normally suppresses T cell proliferation) and IL-1 cluster (IL-1RA) associated with severe AA
Rook's 5e, p. 1400

Clinical Features

Morphological Types / Patterns

Pattern	Description
Patchy AA	Single or multiple round/oval well-circumscribed smooth bald patches, 1-5 cm
Alopecia Totalis (AT)	Complete loss of all scalp hair
Alopecia Universalis (AU)	Complete loss of all body hair including scalp
Ophiasis	Band-like loss along temporal and occipital scalp periphery - poor prognosis
Sisaipho (Ophiasis inversus)	Spares temporal/occipital; diffuse involvement elsewhere
Reticular	Recurrent patches - hair loss in one area while regrowth in another
Diffuse AA	Widespread thinning mimicking AGA or telogen effluvium - diagnosis challenge
AA incognita	Acute diffuse loss without visible patches; positive pull test; many yellow dots

Cardinal Signs

Smooth scalp surface within patches (vs. scarring alopecia)
Exclamation point hairs - proximal tapering, blunt distal end; at active patch margins - pathognomonic
Black dots (cadaver hairs) - broken hairs visible at follicular ostia
Yellow dots - empty follicles filled with keratotic material and sebum
Sparing of white/grey hairs (early disease)
Canities subita - apparent sudden whitening when all pigmented hairs fall out simultaneously

Nail Changes (in ~10%, more in severe/extensive disease)

Nail pitting (most common) - geometric, grid-like pattern
Trachyonychia - sandpaper-like roughness, longitudinal ridging
Brittle nails, onycholysis, koilonychia, onychomadesis, red lunulae

Trichoscopy (Dermoscopy) - Key Feature

Trichoscopy of AA: yellow dots and black dots at baseline (A), resolution after treatment (B)

Trichoscopy: (A) active AA - yellow dots, black dots, exclamation mark hairs; (B) post-treatment resolution with normal hair regrowth

Trichoscopic Feature	Meaning	Activity
Yellow dots	Empty follicles + keratotic/sebaceous plugs	Active/chronic
Black dots	Broken hair shafts at ostia	Active
Exclamation point hairs	Proximal thinning due to arrested mitosis	Active (moderate)
Tapered hairs	Very long exclamation point hairs	Active (moderate)
Pigtail/circle hairs	Regrowing hairs curling	Regrowth
Upright regrowing hairs	Short stubble emerging	Regrowth

AAPS (Alopecia Areata Predictive Score) uses trichoscopy findings to estimate regrowth probability. - Rook's 5e, p. 1400

Histopathology

Acute/Early/Progressive Phase:

Normal total hair count
Peribulbar mononuclear infiltrate - predominantly CD4+ and CD8+ T cells + NK cells around anagen/catagen bulbs - "swarm of bees"
Occasional eosinophils, mast cells
Degenerative changes in hair matrix
Increased catagen/telogen hairs
Trichomalacia, pigment casts

Chronic/Longstanding Phase:

Miniaturization of most follicles - "nanogen hairs" (arrested, rapidly cycling miniaturized hairs)
Mild peribulbar infiltrate around nanogen bulbs
Follicular dropout possible in very long-standing disease (>10 years)

Key histology pearl: AA should be considered whenever high percentages of telogen or miniaturized hairs are found even without peribulbar inflammation (as the infiltrate may be absent in chronic disease). - Fitzpatrick's, p. 1548

Rook's 5e, p. 1400-1401

Associated Conditions / Comorbidities

Association	Odds Ratio / Note
Thyroid disease (Hashimoto's)	OR 4.4
SLE	OR 3.5
Atopic dermatitis	OR 2.4
Vitiligo	Common co-occurrence
Down syndrome	Increased incidence
APECED syndrome	AA in 1/3 of patients
Vitamin D-dependent rickets type II	Familial association
Depression and anxiety	Psychological comorbidity
Metabolic syndrome	Reported

Routine screening for associated diseases is not recommended unless clinical signs/symptoms prompt it. - Andrews', p. 864

Differential Diagnosis

Condition	Differentiating Feature
Tinea capitis	Broken hairs, scaling, fluorescence, KOH positive
Trichotillomania	Irregular shape, varying hair lengths, hook/coiled hairs on trichoscopy, no inflammation
Androgenetic alopecia	Gradual onset, androgenic pattern, no exclamation point hairs
Telogen effluvium	Diffuse, pull test positive but no yellow/black dots
Secondary syphilis	"Moth-eaten" alopecia; plasma cells on biopsy
Temporal triangular alopecia	Congenital; triangular patch; vellus hairs on trichoscopy
Early scarring alopecia	Follicular ostia lost; inflammation; biopsy diagnostic
Loose anagen syndrome	Hair pulls easily without taper
Alopecia neoplastica	Metastatic deposits; scalp induration

Prognosis

Good prognosis factors:

Single small patch
Short disease duration
Postpubertal onset
No nail changes
No family history

Poor prognosis factors (IADVL / Fitzpatrick's):

Ophiasis pattern
Onset in childhood
Extensive involvement (>50% scalp)
Nail changes present
Duration >5 years (may be irreversible >10 years)
Atopic dermatitis comorbidity
Involvement of occiput/hairline

Spontaneous remission rates:

~60% partial regrowth by 1 year
~25% have only a single episode
~40% relapse within first year
Fitzpatrick's, p. 1548 | Andrews', p. 869

Treatment

Treatment Algorithm by Extent

Limited disease (< 50% scalp / SALT ≤ 20)
    ↓
Intralesional triamcinolone ± topical steroids
    ↓
No response → topical immunotherapy (DPCP/SADBE)

Extensive disease (> 50% scalp / SALT > 20)
    ↓
Systemic: Oral JAK inhibitors (first choice now)
          OR pulse corticosteroids
          OR cyclosporine / methotrexate

1. Intralesional Corticosteroids (IL-CS) - First line for patchy AA

Triamcinolone acetonide 2.5-10 mg/mL (Rook's recommends 2.5-5 mg/mL)
0.1 mL per injection site, 1 cm apart, into mid-deep dermis
Maximum dose per session: 10-20 mg (Rook's 5e)
Repeat every 3-4 weeks
Risk: skin atrophy with high concentrations; retinal artery embolization with high pressure injection (Andrews')

2. Topical Corticosteroids

Class I (ultrapotent) corticosteroids - first-line topical
Less reliable than intralesional; suitable as first-line in children
Safer than injections

3. Oral/Pulse Corticosteroids (for rapidly progressive or widespread disease)

Regimen	Protocol
Daily prednisolone	0.4-0.6 mg/kg/day, taper over ≥12 weeks
Pulse dexamethasone	0.1 mg/kg twice weekly
Prednisolone pulse	200 mg weekly (adults); 5 mg/kg monthly
Methylprednisolone	500 mg/day × 3 days monthly (Kaposi-type pulse)

Ophiasis does not respond to pulse steroids
Predictors of response to pulse steroids: duration <6 months, onset <10 years, multifocal disease

4. JAK Inhibitors - Current Standard for Severe AA

Drug	Type	Status	Notes
Baricitinib	Oral JAK1/2 inhibitor	FDA-approved for severe AA in adults	First approved
Ritlecitinib	Oral JAK3/TEC inhibitor	FDA-approved for AA + extensive hair loss ≥12 years	Approved for adolescents too
Tofacitinib	Oral JAK1/3 inhibitor	Off-label	Good evidence
Ruxolitinib (oral)	Oral JAK1/2 inhibitor	Off-label
Topical ruxolitinib 1.5%	Topical	Less effective than oral
Topical tofacitinib 2%	Topical	Less effective than oral

Maintenance therapy is necessary to avoid relapse after stopping JAK inhibitors. - Rook's 5e, p. 1402

Low-dose oral minoxidil can be added as supplemental therapy alongside any primary treatment. - Rook's 5e

5. Contact Immunotherapy (for refractory / widespread / children with severe disease)

Diphencyprone (DCP/DPCP) - most used in practice
Squaric acid dibutyl ester (SADBE)
Mechanism: induces contact hypersensitivity → shifts T cell response away from follicle
Note: avoid concurrent systemic immunosuppressants as they blunt the desired contact reaction

6. Steroid-Sparing Systemic Agents

Drug	Dose	Notes
Cyclosporine	3-5 mg/kg/day	Can combine with PUVA
Methotrexate	15-20 mg/week (adults); 0.4 mg/kg/week (children)
Mycophenolate mofetil	-	Limited data
Azathioprine	-	Limited data
Sulfasalazine	Up to 1.5 g three times daily

7. Other Therapies

PUVA (topical or oral) - for refractory/widespread lesions
Topical anthralin 1% (short contact 15-20 min, then shampooed off)
Topical minoxidil - as adjunct
Excimer laser (308 nm) - 300-2300 mJ/cm² per session; 11-12 sessions over 9-11 weeks
Bimatoprost / latanoprost - for eyelash/eyebrow disease (prostaglandin analogues); note periocular pigmentation risk
Dupilumab - successful when AA occurs with comorbid atopic dermatitis

Treatment for Children

Topical Class I steroids first
Contact immunotherapy (DPCP) before systemic options
Pulse corticosteroids: prednisolone 5 mg/kg (up to 300 mg) monthly
JAK inhibitors in children: off-label; ritlecitinib approved ≥12 years; max baricitinib 0.625 mg (<20 kg) to 1.25 mg (20-40 kg)

Scoring Tools

SALT score (Severity of Alopecia Tool): Most widely used; SALT >20 = indication for systemic therapy
AAPS (Alopecia Areata Predictive Score): Based on trichoscopy; estimates regrowth probability

Psychological Aspect (IADVL emphasis)

AA causes significant psychological morbidity - depression, anxiety, social withdrawal, poor self-esteem. Patient education about:

Disease process and natural course
High rate of spontaneous remission
Cosmetic alternatives (wigs)
Support organizations (National Alopecia Areata Foundation)

Summary of Key Points (High-Yield)

Feature	Key Point
Type	Non-scarring, autoimmune
Target	Anagen hair bulb (NOT bulge/stem cells)
Key cell	CD8+NKG2D+ cytotoxic T cells
Key cytokine	IFN-γ (Th1 driven)
Pathway	JAK-STAT (drives IFN-γ/IL-15 signaling)
Hallmark sign	Exclamation point hairs
Trichoscopy triad	Yellow dots + Black dots + Exclamation point hairs
Histology	Peribulbar "swarm of bees" infiltrate
White hair spared?	Yes (melanocytes are the target)
Nail change	Nail pitting (grid-like) most common
Best prognosis	Single patch, short duration, postpubertal
Worst prognosis	Ophiasis, childhood onset, atopy, nails involved
FDA-approved treatments	Baricitinib (adults), Ritlecitinib (≥12 yrs)
First-line limited disease	Intralesional triamcinolone
First-line severe disease	Oral JAK inhibitors
Contact allergens used	DPCP, SADBE, DNCB

Sources:

Fitzpatrick's Dermatology 9th ed., Ch. 13 (p. 229) and Ch. 87 (pp. 1546-1550)
Rook's Dermatology 5e (Dermatology 2-Volume Set), Ch. 69 (pp. 1399-1403)
Andrews' Diseases of the Skin, Ch. 33 (pp. 864-870)
IADVL approach: consistent with above; pulse steroids and DPCP are pillars of Indian practice (IJDVL)

This is a shared conversation. Sign in to Orris to start your own chat.